Keri Urwin joined Halloran Consulting Group in 2013. She has more than 14 years of experience in Clinical Trial Management.  Keri has expertise leading large global teams and has led many projects, Phases I-IV, from study start through regulatory submission.  Keri has significant therapeutic experience in neurology, pain management and PE/DVT as well as experience in CHF and Oncology.

Prior to joining Halloran, Keri spent five years at Biogen Idec where she focused on Multiple Sclerosis (MS) trials for Avonex and Tysabri and was part of the submission team responsible for FDA approval of Tysabri.  She spent two years at GlaxoSmithKline where she was a Lead Study Manager assigned to various global trials focusing on restless leg syndrome and MS.  Keri has spent the last six years working as a consultant for Pfizer on pain management and PE/DVT trials. Keri earned a Master of Business Administration from Meredith College in Raleigh, NC and a Bachelor of Arts in Psychology from University of Iowa.